Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the active compound in turmeric, has attracted scientific interest for its potential role in supporting or treating Alzheimer’s Disease (AD). The rationale stems from curcumin’s anti-inflammatory, antioxidant, and anti-amyloid properties demonstrated in preclinical studies. Laboratory and animal research has shown that curcumin can inhibit beta-amyloid plaque formation, reduce oxidative stress, and decrease neuroinflammation—three key factors implicated in the pathology of AD. Epidemiological data also suggests lower rates of AD in populations with high dietary turmeric intake, though causality is unproven.

However, the quality and quantity of clinical evidence in humans remain limited. Several small-scale trials have tested curcumin supplementation in AD patients, but most have failed to demonstrate significant cognitive benefits, often due to issues such as poor bioavailability of curcumin, short study durations, and small sample sizes. Some newer formulations with enhanced bioavailability are under investigation, but robust, large-scale clinical data are lacking.

Overall, while there is a plausible scientific rationale and preclinical support for curcumin’s potential benefit in AD, current clinical evidence is insufficient to confirm efficacy. Thus, curcumin’s use for Alzheimer’s is justified more by emerging scientific interest and preliminary findings than by definitive proof or longstanding traditional use specifically for this condition.

More about curcumin
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by curcumin

Products containing curcumin

Nature's Sunshine Turmeric Curcumin (Formerly CurcuminBP)